Oligonucleotide Therapeutics Market worth $17.70 billion by 2030
The report "Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region – Global Forecast to 2030" is projected to grow from USD 7.19 billion in 2025 and to reach USD 17.70 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 19.7% during the forecast period.
Browse 450 market data Tables and 40 Figures spread through 400 Pages and in-depth TOC on "Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region – Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-therapeutics-market-41710113.html
A key driver is the expanding number of pharma and biotech companies developing ASO and siRNA pipelines in neurology, cardiometabolic conditions, and rare diseases. This maintains high demand for GMP-grade, high-purity oligonucleotide drug substances and leads to increased spending on advanced synthesis chemistries, purification, and analytical release testing.
Nusinersen was the largest molecule segment in 2024.
Globally, nusinersen (SPINRAZA) secured the leading market position in 2024. This is mainly because nusinersen is one of the most well-known and widely used oligonucleotide drugs in clinical practice. It has been employed in neurology, specialty care, and repeat dosing for a long time. Therefore, it continues to generate demand.
Neurological disorders surpassed other disease types in 2024.
Neurological disorders held the largest market share in 2024, primarily driven by the strong commercial presence of established oligonucleotide drugs in neurology and neuromuscular care. Many neurological conditions treated with oligo therapies require specialist-led treatment and repeated dosing. This supports ongoing demand and steady revenue flow. Neurology programs also tend to use high-value, controlled substances because safety and consistency are crucial in these patient groups.
North America is expected to lead the oligonucleotide therapeutics market during the forecast period.
North America is expected to be the largest market for oligonucleotide therapeutics during the forecast period. The region has a high number of pharmaceutical and biotech companies specializing in RNA. This is driving the growth of the ASO and siRNA pipelines. Consequently, the demand for GMP-grade oligonucleotide drug substance increases across preclinical, clinical, and commercial stages.
Key companies active in the oligonucleotide therapeutics market include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Azenta US Inc. (US), and Ionis Pharmaceuticals, Inc. (US).
Don’t miss out on business opportunities in Oligonucleotide Therapeutics Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Therapeutics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
